DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer.
We have also acquired certain exclusive commercial rights in China where VAL-083 is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer.
We are dedicated to benefiting patients and creating shareholder value by rapidly developing and commercializing anti-cancer therapies in cancer indications where patients have failed or are unlikely to respond to modern therapy.